Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

9 listopada 2026 zaktualizowane przez: Orca Biosystems, Inc.

Wieloośrodkowe badanie fazy 1 allogenicznego przeszczepu komórek hematopoetycznych dla pierwotnego postępującego stwardnienia rozsianego za pomocą Orca-Q, inżynierii przeszczep dawcy pochodzącego z zmobilizowanej krwi obwodowej krwi

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

Przegląd badań

Szczegółowy opis

This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

10

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: James S. McClellan, MD, PhD
  • Numer telefonu: 650-246-9601
  • E-mail: info@orcabio.com

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria (Recipient):

  1. Participants aged ≥18 and ≤65 years with PPMS

    a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision

  2. Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands

  3. EDSS between 2.0 and 5.5 inclusive

  4. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)

  5. Eligibility criteria confirmed by the Eligibility Review Group

  6. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0

  7. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT

  8. Willing to undergo MAC preparative regimen

  9. Matched to either a related or unrelated donor as follows:

    1. Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    2. Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  10. Negative serum or urine β-HCG test in persons of childbearing potential

Exclusion Criteria:

  1. History of Progressive Multifocal Leukoencephalopathy

  2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:

    1. Renal insufficiency as defined by an estimated GFR <60 mL/minute
    2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
    3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
    4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
    5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
    6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
    7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
    8. Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
  3. History of smoking either tobacco or other herbal products in the last 3 months

  4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol

  5. HIV seropositive

  6. HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant

  7. HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy

  8. Participant has active uncontrolled infection

  9. Participant has demonstrated lack of compliance with prior medical care

  10. Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.

  11. Participants whose life expectancy is severely limited by illness other than multiple sclerosis

  12. Females who are pregnant or breast feeding

  13. Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol

  14. Inability to undergo an MRI scan

  15. Currently receiving treatment with investigational agents

  16. Positive for JC virus DNA in the CSF or blood during screening

  17. Known allergy or hypersensitivity to or intolerance of tacrolimus

  18. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins

  19. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:

    1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    2. Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  20. People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Orca-Q Graft with myeloablative conditioning regimen

Donor Orca-Q stem cell graft

Allogeneic (donor) stem cell graft

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

Inne nazwy:
  • busulfan
  • fludarabina
  • tiotepa

Graft-versus-host disease (GVHD) prevention

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Severe acute graft-versus-host-disease-free survival
Ramy czasowe: Up to 6 months after infusion

Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse)

Up to 6 months after infusion

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Event-Free Survival (EFS)
Ramy czasowe: Up to 24 months and at year 5 after Orca-Q infusion

Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death

Up to 24 months and at year 5 after Orca-Q infusion
Loss of Neurological Function or Relapse
Ramy czasowe: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant

Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse

Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
Overall Survival (OS)
Ramy czasowe: From transplant through 5 years after transplant

Time in years from transplant to death from any cause

From transplant through 5 years after transplant
Treatment-Related Mortality (TRM)
Ramy czasowe: From start of alloHCT through 5 years after transplant

Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data

From start of alloHCT through 5 years after transplant
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
Ramy czasowe: From Orca-Q infusion through 5 years after transplant

Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded

From Orca-Q infusion through 5 years after transplant
Incidence of aGVHD
Ramy czasowe: From transplant through 5 years after transplant

Number of participants with aGVHD

From transplant through 5 years after transplant
Severity of aGVHD
Ramy czasowe: From transplant through 5 years after transplant

Severity is graded per MAGIC criteria

From transplant through 5 years after transplant
Incidence chronic graft-versus-host disease (cGVHD)
Ramy czasowe: From transplant through 5 years after transplant

Number of participants with cGVHD

From transplant through 5 years after transplant
Severity of cGVHD
Ramy czasowe: From transplant through 5 years after transplant

cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD

From transplant through 5 years after transplant
Incidence of Primary Graft Failure
Ramy czasowe: Through day +28

Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause

Through day +28
Incidence of Secondary Graft Failure
Ramy czasowe: Through day +100

Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause

Through day +100
Time to Neutrophil Engraftment
Ramy czasowe: From transplant through Day +365

Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days.

From transplant through Day +365
Development of Infectious Complications
Ramy czasowe: From transplant through Day +730 (2 years), with long-term follow-up through 5 years

Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation

From transplant through Day +730 (2 years), with long-term follow-up through 5 years
Regimen-Related Toxicity
Ramy czasowe: From start of conditioning through 1 year after transplant

Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse).

From start of conditioning through 1 year after transplant

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 marca 2027

Zakończenie podstawowe (Szacowany)

1 czerwca 2028

Ukończenie studiów (Szacowany)

1 grudnia 2032

Daty rejestracji na studia

Pierwszy przesłany

3 lutego 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

26 marca 2025

Pierwszy wysłany (Rzeczywisty)

28 marca 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj